Analysis Tools
cardiovascular system
|
• mice show an increase in the cross-sectional area of cardiomyocytes at 12 months of age
• intramyocardial AAV9-GPLD1 administration restores cross-sectional areas to wild-type values
|
|
• mice show an increase in heart weight to body weight (HW/BW) and heart weight to tibia length (HW/TL) ratios at 12 months of age
• intramyocardial AAV9-GPLD1 administration restores these ratios to wild-type values
|
|
• mice exhibit an exaggerated cardiac hypertrophy phenotype with markedly increased protein levels of hypertrophic markers (NPPA/ANF and MYH7/beta-MHC) in cardiac tissues at 12 months of age
• intramyocardial AAV9-GPLD1 administration reduces the protein levels of hypertrophic markers and reverses this pathology
|
|
• 12-month-old mice show an increase in LV size
|
|
• 12-month-old mice show an increase in LV wall thickness
|
|
• mice exhibit an increased collagen volume in cardiac tissues at 12 months of age
• intramyocardial AAV9-GPLD1 administration reduces collagen volume to near wild-type baseline levels
|
|
• mice show an age-dependent decline in LV function, as determined by 3-D LV radial strain maps and global longitudinal strain curves; a reduction in ejection fraction (EF) and fractional shortening (FS) is noted at 12 months of age
• intramyocardial injection-mediated delivery of AAV9-GPLD1 significantly improves cardiac function, as evidenced by echocardiographic assessments
|
|
• 12-month-old mice show LV diastolic dysfunction with a significant reduction in the mitral valve E/A ratio (early to late diastolic transmitral flow velocity)
• intramyocardial AAV9-GPLD1 administration significantly improves diastolic function by normalizing the E/A ratio
|
growth/size/body
|
• mice show an increase in heart weight to body weight (HW/BW) and heart weight to tibia length (HW/TL) ratios at 12 months of age
• intramyocardial AAV9-GPLD1 administration restores these ratios to wild-type values
|
|
• mice exhibit an exaggerated cardiac hypertrophy phenotype with markedly increased protein levels of hypertrophic markers (NPPA/ANF and MYH7/beta-MHC) in cardiac tissues at 12 months of age
• intramyocardial AAV9-GPLD1 administration reduces the protein levels of hypertrophic markers and reverses this pathology
|
muscle
|
• mice show an increase in the cross-sectional area of cardiomyocytes at 12 months of age
• intramyocardial AAV9-GPLD1 administration restores cross-sectional areas to wild-type values
|
|
• mice show an age-dependent decline in LV function, as determined by 3-D LV radial strain maps and global longitudinal strain curves; a reduction in ejection fraction (EF) and fractional shortening (FS) is noted at 12 months of age
• intramyocardial injection-mediated delivery of AAV9-GPLD1 significantly improves cardiac function, as evidenced by echocardiographic assessments
|
|
• 12-month-old mice show LV diastolic dysfunction with a significant reduction in the mitral valve E/A ratio (early to late diastolic transmitral flow velocity)
• intramyocardial AAV9-GPLD1 administration significantly improves diastolic function by normalizing the E/A ratio
|
